Novel agents
| Agent . | Comments . |
|---|---|
| IMiDs | |
| Lenalidomide | Approved for MM, MDS |
| Pomalidomide | Phase 2 |
| Syk inhibitors | |
| Fostamatinib disodium | Phase 1, 2 |
| Bruton kinase inhibitors | |
| PCI-32765 | Phase 1 |
| JAK-2 inhibitors | |
| SB1518 | Phase 1 |
| PI3K inhibitors | |
| CAL-101 | Phase 1 |
| AKT inhibitors | |
| Perifosine | Phase 2 |
| mTOR inhibitors | |
| RAD001, temsirolimus | Phase 2, 3 |
| Ras/Raf inhibitors | |
| Sorafenib | Approved for liver, renal cancer |
| Tipifarnib | Phase 3 |
| PKC inhibitors | |
| Enzastaurin | Phase 2 |
| NFκB inhibitors | |
| Bortezomib | Approved for MM, MCL |
| Carfilzomib | Phase 2 |
| HDAC inhibitors | |
| Vorinostat | Approved for CTCL |
| Romidepsin | Approved for CTCL |
| LBH589, MGCD0103 | Phase 2 |
| Bcl-2 inhibitors | |
| ABT-263 Obatoclax | Phase 2 |
| Unique agents | |
| Pralatrexate | Approved for PTCL |
| Bendamustine | Approved for CLL, NHL |
| Denileukin diftitox | Approved for CD25+ CTCL |
| Agent . | Comments . |
|---|---|
| IMiDs | |
| Lenalidomide | Approved for MM, MDS |
| Pomalidomide | Phase 2 |
| Syk inhibitors | |
| Fostamatinib disodium | Phase 1, 2 |
| Bruton kinase inhibitors | |
| PCI-32765 | Phase 1 |
| JAK-2 inhibitors | |
| SB1518 | Phase 1 |
| PI3K inhibitors | |
| CAL-101 | Phase 1 |
| AKT inhibitors | |
| Perifosine | Phase 2 |
| mTOR inhibitors | |
| RAD001, temsirolimus | Phase 2, 3 |
| Ras/Raf inhibitors | |
| Sorafenib | Approved for liver, renal cancer |
| Tipifarnib | Phase 3 |
| PKC inhibitors | |
| Enzastaurin | Phase 2 |
| NFκB inhibitors | |
| Bortezomib | Approved for MM, MCL |
| Carfilzomib | Phase 2 |
| HDAC inhibitors | |
| Vorinostat | Approved for CTCL |
| Romidepsin | Approved for CTCL |
| LBH589, MGCD0103 | Phase 2 |
| Bcl-2 inhibitors | |
| ABT-263 Obatoclax | Phase 2 |
| Unique agents | |
| Pralatrexate | Approved for PTCL |
| Bendamustine | Approved for CLL, NHL |
| Denileukin diftitox | Approved for CD25+ CTCL |
CLL indicates chronic lymphocytic lymphoma; CTCL, cutaneous T-cell lymphoma; HDAC, histone deacetylase; IMiD, immunomodulatory; JAK-2, Janus kinase 2; NHL, non-Hodgkin lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; mTOR, mammalian target of rapamycin; NFκB, nuclear factor kappa B; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; and PTCL, peripheral T-cell lymphoma.